M&A

News

Sanofi buys UK's Kymab and inflammatory disease hopeful for ...

Sanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big French pharma seeks to add to its pipeline of drugs that treat inflammatory diseases and cancer.

News

Bioclinica boosts digital trial credentials with Saliency bu...

With the ink barely dry on its last merger agreement, clinical trial and imaging specialist Bioclinica is on an expansive drive once again, buying digital clinical trial specialist Saliency

News

Illustration of a nerve cell on a colored background with light effects

Angelini and Arvelle create neurology player with $960m merg...

There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based ar

News

BMS/Celgene merger payout evaporates as CVR deadline passes

Former Celgene shareholders holding on for a windfall payment from Bristol-Myers Squibb tied to FDA approval of three late-stage drugs saw their hopes dashed as 2020 drew to a close.

News

Servier beefs up in cancer, buying Agios’ oncology business ...

French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on gen

Views & Analysis